Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva’s Copaxone Shows Continued Efficacy In Long-Term Trial; Study Extended To 15 Years

This article was originally published in The Pink Sheet Daily

Executive Summary

Teva reported no cases of immune-mediated adverse events in a 10-year study of its multiple sclerosis therapy glatiramer.

You may also be interested in...



Teva To Investigate High-Dose Copaxone

A Phase III trial will compare 40 mg/day glatiramer to the 20 mg/day approved dose.

Teva To Investigate High-Dose Copaxone

A Phase III trial will compare 40 mg/day glatiramer to the 20 mg/day approved dose.

Copaxone Sales Will Continue Growth Regardless Of Tysabri Re-Launch, Teva Says

Teva expects sales of its multiple sclerosis therapy Copaxone (glatiramer)to continue to grow in 2006 regardless of whether FDA allows the re-launch of competitor Tysabri (natalizumab)

Related Content

Topics

UsernamePublicRestriction

Register

LL1131980

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel